Duality Advisers LP Purchases Shares of 79,714 InMode Ltd. (NASDAQ:INMD)

Duality Advisers LP acquired a new position in InMode Ltd. (NASDAQ:INMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 79,714 shares of the healthcare company’s stock, valued at approximately $1,773,000. Duality Advisers LP owned 0.10% of InMode as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Janney Montgomery Scott LLC increased its holdings in InMode by 1.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 40,278 shares of the healthcare company’s stock worth $1,227,000 after acquiring an additional 601 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of InMode by 1.9% in the third quarter. Los Angeles Capital Management LLC now owns 33,916 shares of the healthcare company’s stock worth $1,033,000 after purchasing an additional 640 shares during the period. CWM LLC increased its stake in shares of InMode by 38.3% in the fourth quarter. CWM LLC now owns 2,454 shares of the healthcare company’s stock worth $55,000 after purchasing an additional 680 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of InMode by 2.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,643 shares of the healthcare company’s stock valued at $793,000 after purchasing an additional 701 shares during the period. Finally, Exchange Traded Concepts LLC purchased a new position in shares of InMode during the 3rd quarter valued at $27,000. Institutional investors own 68.04% of the company’s stock.

InMode Stock Down 1.6 %

INMD opened at $17.14 on Tuesday. The company has a market capitalization of $1.44 billion, a PE ratio of 7.45 and a beta of 2.16. The firm has a 50-day simple moving average of $20.80 and a two-hundred day simple moving average of $21.80. InMode Ltd. has a 52 week low of $16.96 and a 52 week high of $48.25.

InMode (NASDAQ:INMD) last posted its earnings results on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. InMode had a return on equity of 29.80% and a net margin of 40.22%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.69 earnings per share. As a group, sell-side analysts expect that InMode Ltd. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on INMD. UBS Group increased their price target on InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 14th. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research report on Tuesday, April 9th. Finally, Barclays decreased their target price on InMode from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, April 12th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $32.80.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.